当前位置: X-MOL 学术J. Card. Surg. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Transcatheter mitral valve therapies: State of the art
Journal of Cardiac Surgery ( IF 1.6 ) Pub Date : 2021-09-16 , DOI: 10.1111/jocs.15995
Sarah Yousef 1 , George J Arnaoutakis 2 , Hemal Gada 3 , Anson Jay Conrad Smith 3 , Saurabh Sanon 3 , Ibrahim Sultan 1, 3
Affiliation  

Mitral regurgitation (MR) is one of the most prevalent valvular pathologies in the developed world. There continues to be a growing population of aging patients with MR who may be too high risk for surgical management. The rapid adoption and remarkable success of transcatheter aortic valve replacement (TAVR) generated enthusiasm for transcatheter mitral valve therapies; however, the complex anatomy and pathophysiology of the mitral valve confers several unique challenges for a fully percutaneous approach. Nevertheless, several devices are under development and in various phases of preclinical or clinical testing, both for transcatheter mitral valve replacement and repair. MitraClip (Abbott Vascular), which has received FDA approval, is the most established percutaneous repair strategy and has been performed in over 80,000 patients as of 2019. The following article serves as a review of the available and upcoming devices for the various etiologies of mitral valvular disease, as well as the unique challenges and potential complications of transcatheter mitral valve intervention.

中文翻译:

经导管二尖瓣疗法:最先进的技术

二尖瓣关闭不全 (MR) 是发达国家中最普遍的瓣膜病变之一。越来越多的老年 MR 患者可能手术治疗的风险过高。经导管主动脉瓣置换术 (TAVR) 的迅速采用和显着成功激发了对经导管二尖瓣治疗的热情;然而,二尖瓣的复杂解剖结构和病理生理学为完全经皮手术带来了几个独特的挑战。尽管如此,一些装置正在开发中,并处于临床前或临床测试的各个阶段,用于经导管二尖瓣置换和修复。已获得 FDA 批准的 MitraClip(雅培血管)是最成熟的经皮修复策略,截至 2019 年已在超过 80,000 名患者中进行。
更新日期:2021-09-16
down
wechat
bug